Abstract:BackgroundUnderstanding the progression of prostate cancer to androgen-independence/castrate resistance and development of preclinical testing models are important for developing new prostate cancer therapies. This report describes studies performed 30 years ago, which demonstrate utility and shortfalls of xenografting to preclinical modeling.MethodsWe subcutaneously implanted male nude mice with small prostate cancer fragments from transurethral resection of the prostate (TURP) from 29 patients. Successful xe… Show more
“…Due to different immunological impairments, it is assumed that the more permissive mouse strains such as NOD-SCID, SCID or NSG, can strongly increase the efficiency of xenotransplantation, as compared to nude mice. Indeed, a very low tumour rate take (10–25%) was reported after implanting tumour fragments of different histotypes in nude mice [8–10]. The use of NOD-SCID resulted in an increased engraftment rate (25–40%) for non-small cell lung cancer, breast cancer and melanoma [11–15] and a very high tumour take-rate (from 50 to 80%) has been observed for ovarian cancer, head and neck tumours, metastatic colon and bladder cancer [6, 16–18].…”
Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the ‘right’ treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.
“…Due to different immunological impairments, it is assumed that the more permissive mouse strains such as NOD-SCID, SCID or NSG, can strongly increase the efficiency of xenotransplantation, as compared to nude mice. Indeed, a very low tumour rate take (10–25%) was reported after implanting tumour fragments of different histotypes in nude mice [8–10]. The use of NOD-SCID resulted in an increased engraftment rate (25–40%) for non-small cell lung cancer, breast cancer and melanoma [11–15] and a very high tumour take-rate (from 50 to 80%) has been observed for ovarian cancer, head and neck tumours, metastatic colon and bladder cancer [6, 16–18].…”
Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the ‘right’ treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.
“…In contrast, when the testosterone level was insufficient, the cycle of prostate proliferation was affected, and showed an abnormal epithelium, that is, poor differentiation. This phenomenon is related to the relationship between a low testosterone level and high-grade, that is poorly differentiated prostate cancer [25,26].…”
ObjectiveTo investigate the relationship between low testosterone levels and prostate cancer detection risk in a biopsy population.
Patients and MethodsIn all, 681 men who underwent initial 12-core transrectal prostate biopsy at our institution were included in this retrospective study. Patients were divided into groups with low (<300 ng/dL) and normal testosterone levels (≥300 ng/ dL). Clinical and pathological data were analysed.
ResultsAmong 681 men, 86 men (12.6%) had low testosterone levels, 143 (32.7%) had a positive biopsy, and 99 (14.5%) had highgrade prostate cancer. The mean age, prostate-specific antigen (PSA) level, PSA density, body mass index (BMI), number of abnormal digital rectal examination (DRE) findings, and diabetes mellitus (DM) history were significantly different between the low and normal level testosterone groups. A low testosterone level was significantly associated with a higher risk of detection of overall prostate cancer than a normal testosterone level in univariate analysis (odds ratio [OR] 2.545, P = 0.001), but not in multivariate analysis adjusting for parameters such as age, PSA, prostate volume, BMI, abnormal DRE findings and DM (OR 1.583, P = 0.277). Meanwhile, a low testosterone level was significantly related to a higher rate of high-grade prostate cancer compared with a normal testosterone level in univariate (OR 3.324, P < 0.001) and multivariate analysis adjusting for other parameters (OR 2.138, P = 0.035).
ConclusionLow testosterone level is an independent risk factor for highgrade prostate cancer detection at biopsy. Therefore, checking testosterone levels could help to determine whether prostate biopsy should be carried out.
“…This can be done using tissue obtained during surgery, or through needle biopsy at diagnosis 117 . Prostate tumors have been difficult to establish, as they require high quality tumor tissue and thorough characterization 117–122 . While PDX models capture more of the genomic, epigenetic, and proteomic diversity within prostate cancer, it has been difficult to use PDXs for drug discovery 123 .…”
Section: Introductionmentioning
confidence: 99%
“…It is believed, however, that PDXs represent the future of personalized or individualized medicine – each patient will some day be able to have their tumor grown as a PDX (or avatar) and analyzed for genomic alterations, identifying actionable targets for therapy 123 . Lessons learned from the many existing and ever-increasing number of PDXs should facilitate the harnessing of this technology for novel biological discoveries at each stage of prostate cancer 122 .…”
Introduction
The mouse is an important, though imperfect, organism with which to model human disease and to discover and test novel drugs in a preclinical setting. Many experimental strategies have been used to discover new biological and molecular targets in the mouse, with the hopes of translating these discoveries into novel drugs to treat prostate cancer in humans. Modeling prostate cancer in the mouse, however, has been challenging, and often drugs that work in mice have failed in human trials.
Areas covered
Here we discuss similarities and differences between mice and men, types of mouse models that exist to model prostate cancer, practical questions one must ask when using a mouse as a model, and potential reasons that drugs do not often translate to humans. We will also discuss the current value in using mouse models for drug discovery to treat prostate cancer and what needs are still unmet in field.
Expert opinion
With proper planning and following practical guidelines by the researcher, the mouse is a powerful experimental tool. The field lacks genetically engineered metastatic models, and xenograft models do not allow for the study of the immune system during the metastatic process. There remain several important limitations to discovering and testing novel drugs in mice for eventual human use, but these can often be overcome. Overall, mouse modeling is an essential part of prostate cancer research and drug discovery. Emerging technologies and better and ever-increasing forms of communication are moving the field in a hopeful direction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.